文献速递哮喘

重度哮喘患者多病共存的经济负担:一项基于人群的20年研究

Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study.
PubMed 文献 · Thorax · 2019-09-18

该研究利用加拿大不列颠哥伦比亚省1996-2016年健康行政数据,识别重度哮喘患者并匹配非重度哮喘及非哮喘人群,估算共病带来的增量医疗成本。结果显示,相对于非哮喘人群,重度哮喘每 person-year 增量成本为2779加元(95%CI 2514-3045),其中54%(1508加元)归因于共病;相对于非重度哮喘,增量成本为1922加元(95%CI 1670-2174),52%(1003加元)归因于共病。

要点

  • 重度哮喘的增量医疗成本中超过一半由共病导致。
  • 相对非哮喘,重度哮喘每 person-year 增量成本2779加元,其中1508加元归因共病。
  • 相对非重度哮喘,增量成本1922加元,其中1003加元归因共病。

核心结论

  • 共病占重度哮喘患者增量医疗成本的一半以上,决策时应考虑多病共存负担。

研究设计与样本

  • 基于加拿大不列颠哥伦比亚省1996-2016年健康行政数据的回顾性匹配队列研究,依据药物使用强度和急性加重定义重度哮喘。

主要发现

  • 相对非哮喘,重度哮喘每 person-year 增量成本为2779加元(95%CI 2514-3045),54%(1508加元)归因于共病。
  • 相对非重度哮喘,重度哮喘每 person-year 增量成本为1922加元(95%CI 1670-2174),52%(1003加元)归因于共病。
  • 两组中最昂贵的共病均为非哮喘呼吸系统疾病,分别占468加元(17%)和451加元(23%)。

临床怎么用

  • 在重度哮喘管理中应系统评估共病,以更全面估算医疗负担并指导决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The economic impact of multimorbidity in severe or difficult-to-treat asthma has not been comprehensively investigated. AIMS: To estimate the incremental healthcare costs of coexisting chronic conditions (comorbidities) in patients with severe asthma, compared with non-severe asthma and no asthma. METHODS: Using health administrative data in British Columbia, Canada (1996-2016), we identified, based on the intensity of drug use and occurrence of exacerbations, individuals who experienced severe asthma in an incident year. We also constructed matched cohorts of individuals without an asthma diagnosis and those who had mild/dormant or moderate asthma (non-severe asthma) throughout their follow-up. Health service use records during follow-up were categorised into 16 major disease categories based on the International Classification of Diseases. Incremental costs (in 2016 Canadian Dollars, CAD$1=US$0.75=₤0.56=€0.68) were estimated as the adjusted difference in healthcare costs between individuals with severe asthma compared with those with non-severe asthma and non-asthma. RESULTS: Relative to no asthma, incremental costs of severe asthma were $2779 per person-year (95% CI 2514 to 3045), with 54% ($1508) being attributed to comorbidities. Relative to non-severe asthma, severe asthma was associated with incremental costs of $1922 per person-year (95% CI 1670 to 2174), with 52% ($1003) being attributed to comorbidities. In both cases, the most costly comorbidity was respiratory conditions other than asthma ($468 (17%) and $451 (23%), respectively). CONCLUSIONS: Comorbidities accounted for more than half of the incremental medical costs in patients with severe asthma. This highlights the importance of considering the burden of multimorbidity in evidence-informed decision making for patients with severe asthma.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Chen W, Safari A, FitzGerald JM, et al. Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study. Thorax. 2019. PMID: 31534029. doi:10.1136/thoraxjnl-2019-213223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。